During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE about the REACH2 clinical trial. REACH 2 is a phase III study evaluating ruxolitinib vs best available therapy in patients with corticosteroid-refractory acute GvHD following allogeneic stem cell transplantation.
We asked: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
![](https://i.ytimg.com/vi/dy-hvE8Vcqo/maxresdefault.jpg)